Integra LifeSciences price target lowered to $12 from $13 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Integra LifeSciences (IART) to $12 from $13 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds however that given its outlook for the company, the execution overhangs, and uncertainty around whether supply constraints have driven structural damage to end markets, it believes that a discount on the stock is warranted, also noting that Integra’s profit margin and growth profile are below its peers.